Home » Medical Articles » Biomarkers Summit - Discovery, Development & Therapeutics
Biomarkers Summit - Discovery, Development & Therapeutics
SMi proudly presents their 5th annual Biomarkers Summit, taking place on 16th & 17th January at Copthorne Tara Hotel in London, UK.
October 18, 2011 /Medical PR News/ -- SMi proudly presents their 5th annual Biomarkers Summit, taking place on 16th & 17th January at Copthorne Tara Hotel in London, UK.
This year's exciting event will provide a complete picture of developments in the biomarkers field, looking at biomarker development, discovery validation, as well as technological and regulatory updates and advice. Progress of research into therapeutic areas such as oncology, neurodegenerative and respiratory diseases, as well as diabetes will also be discussed.
SMi's Biomarkers Summit 2012 will provide a unique opportunity for debate and problem solving for key challenges facing the biomarkers fields and will present a fantastic platform for networking with senior executives for the pharmaceutical industry.
With biomarkers becoming the most effective tool in drug discovery and development, it is vital that you are kept up-to-date with advances in the field. The 2012 speaker panel consisting of key industry professionals presenting on their expertise in biomarker research, as well as commercialization strategies will equip attendees with the essential information required to succeed in this rapidly developing field.
Key topics to be discussed include:
- Translational biomarkers: Use as a decision making tool in early clinical drug development, development of techniques to identify biomarkers and prediction using PK/PD modelling
- Biomarkers in immunology: Novel inhibitors for use in autoimmune disease, reducing risk in clinical trials and evaluating precision medicine
- Developing neuroscience drugs: Using central activity biomarkers, considering prognostic and diagnostic properties, the benefits of cerebrospinal fluid biomarkers
- Imaging techniques: Establishing pharmcodynamic factors, imaging modalities and discussing what is necessary to validate a biomarker
- Oncology biomarkers: Theranostic development, personalized cancer treatment and patient stratification in oncology biomarker validation
Key Speakers Include:
- Hans Winkler, Senior Director & Global Head, Johnson & Johnson
- Huseyin Mehmet, Director, Exploratory Biomarkers, Merck
- Terry Walker, Director, Translational Immunology, Pfizer
- Gary Gilmour, Senior Research Scientist, Eli Lilly
- Darren Hodgson, Biomics Advisor, AstraZeneca
- Meagan Myers, Staff Fellow, US FDA
Visit our website here: http://www.smi-online.co.uk/biomarkers22.asp
Alternatively or contact Ninica Hussain on: +44 (0) 20 7827 6115
e-mail: nhussain@smi-online.co.uk
About SMi Group
The SMi Group is a world leader in business to business information. With nearly two decades in the business, thousands of senior executives from blue chip companies have already benefited from SMi's highly targeted conferences, workshops and publications. For more information visit www.smi-online.co.uk
For further information, contact:
Ninica Hussain
Tel: +44 (0) 20 7827 6115
Email: nhussain@smi-online.co.uk
---
Press release service and press release distribution provided by http://www.24-7pressrelease.com |
|
|
Press Release Contact Information:
EIN News
|
|
|
|
|
|
|
Advertise With Us |
About Us |
Contact Us